Pfizer expects $20b in COVID-19 vaccine revenue this year
Advertisement Pfizer, the global biotech behind the first COVID-19 vaccine approved in Australia, swung to a small profit in the fourth quarter as it started shipping doses globally. The drugmaker expects roughly $US15 billion ($19.7 billion) in revenue this year from the vaccine, which won emergency clearance in mid-December from US regulators and already has racked up approvals in more than 50 countries. The two-dose vaccine is about 95 per cent effective at preventing coronavirus symptoms and is one of only a few vaccines available to check the global pandemic. Pfizer CEO Albert Bourla sai...